drugset / Trial / NCT04518878
Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm study to investigate the efficacy and safety of the combination of fixed low-dose eltrombopag plus recombinant human thrombopoietin (rhTPO) as treatment for corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients during the COVID-19 pandemic.
Timeline
- Start
- 2020-08-31
- Primary completion
- 2021-12
- Completion
- 2022-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 25 mg | Oral |
| Subject | recombinant human thrombopoietin | Protein / enzyme biologic | 300 iu/kg | Subcutaneous |